Uterine cancer is the most common gynecologic malignancy in the United States, with the American Cancer Society projecting approximately 68,270 new diagnoses and 14,450 deaths in 2026. Incidence and mortality have risen roughly 2% annually since the mid-2000s. Stage matters enormously: five-year survival exceeds 95% when disease is localized, compared to 17-22% at Stage IV. With 67-70% of cases diagnosed at Stage I, recognizing the earliest signals — and documenting them completely — is where primary care has the most to offer.
AAVBC's Uterine Cancer Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering ICD-10 subsite coding, molecular classification, FIGO staging, postmenopausal bleeding recognition, Lynch syndrome surveillance, risk factor documentation, MEAT documentation standards, comorbidity coding for obesity and diabetes, and metastatic site coding. Grounded in current NCCN and SGO guideline evidence, this guide helps care teams catch uterine cancer earlier, document complexity accurately, and keep care coordinated with the continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of uterine cancer — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
Uterine cancer is the most common gynecologic malignancy in the United States, with the American Cancer Society projecting approximately 68,270 new diagnoses and 14,450 deaths in 2026. Incidence and mortality have risen roughly 2% annually since the mid-2000s. Stage matters enormously: five-year survival exceeds 95% when disease is localized, compared to 17-22% at Stage IV. With 67-70% of cases diagnosed at Stage I, recognizing the earliest signals — and documenting them completely — is where primary care has the most to offer.
AAVBC's Uterine Cancer Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering ICD-10 subsite coding, molecular classification, FIGO staging, postmenopausal bleeding recognition, Lynch syndrome surveillance, risk factor documentation, MEAT documentation standards, comorbidity coding for obesity and diabetes, and metastatic site coding. Grounded in current NCCN and SGO guideline evidence, this guide helps care teams catch uterine cancer earlier, document complexity accurately, and keep care coordinated with the continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of uterine cancer — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
